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Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, IndiaAbstractFew studies have systematically standardised and evaluated matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry
(MALDI-TOF MS) for identiﬁcation of yeasts from bloodstream infections. This is rapidly becoming pertinent for early identiﬁcation of
yeasts and appropriate antifungal therapy. We used 354 yeast strains identiﬁed by polymerase chain reaction (PCR) sequencing for
standardisation and 367 blind clinical strains for validation of our MALDI-TOF MS protocols. We also evaluated different sample
preparation methods and found the on-plate formic acid extraction method as most cost- and time-efﬁcient. The MALDI-TOF assay
correctly identiﬁed 98.9% of PCR-sequenced yeasts. Novel main spectrum projections (MSP) were developed for Candida auris,
C. viswanathii and Kodamaea ohmeri, which were missing from the Bruker MALDI-TOF MS database. Spectral cut-offs computed by
receiver operating characteristics (ROC) analysis showed 99.4% to 100% accuracy at a log score of 1.70 for C. tropicalis, C. parapsilosis,
C. pelliculosa, C. orthopsilosis, C. albicans, C. rugosa, C. guilliermondii, C. lipolytica, C. metapsilosis, C. nivariensis. The differences in the species-
speciﬁc scores of our standardisation and blind validation strains were not statistically signiﬁcant, implying the optimal performance of
our test protocol. The MSPs of the three new species also were validated. We conclude that MALDI-TOF MS is a rapid, accurate and
reliable tool for identiﬁcation of bloodstream yeasts. With proper standardisation, validation and regular database expansion, its efﬁciency
can be further enhanced.
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E-mail: arunaloke@hotmail.comIntroductionCandida species are among the most common fungi causing
nosocomial bloodstream infections and are associated with
high mortality [1,2]. Candida albicans, C. tropicalis,
C. parapsilosis, C. krusei and C. glabrata are the predominantMicrobiol Infect 2015; 21: 372–378
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.009candidemia agents, but other less common Candida spp. and
yeasts also are emerging as signiﬁcant pathogens [3]. Aside
from emergence of new pathogenic species, increasing anti-
fungal resistance, especially to azoles, is a growing concern [4].
Bloodstream fungal infections exert a substantial toll in terms
of prolonged hospital stay, health care costs, morbidity and
mortality [5]. Rapid species identiﬁcation can facilitate early
institution of suitable antifungal therapy and expedite recovery
in high-risk patients [6]. This is even more pertinent for
emerging rare yeasts resistant to multiple antifungal agents [7].
Conventional phenotyping, although useful for routine iden-
tiﬁcation of common Candida species, is time consuming and
inept at identifying rare yeasts. In contrast, identiﬁcation byious Diseases. Published by Elsevier Ltd. All rights reserved
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and reliable alternative [8]. However, despite its advantages, it
entails a steep learning curve, need for expertise, higher costs
and relatively longer run time than other faster techniques.
Matrix-assisted laser desorption ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS) is rapidly becoming popular for
routine identiﬁcation of clinical pathogens [9]. MALDI-TOF MS
circumvents many challenges posed by other diagnostics and is
being adapted for identiﬁcation of fungi [10,11]. Standardisation
and validation of any novel technique is essential before adopting
it for routine high-throughput diagnostic use. We undertook this
study to standardise and validate MALDI-TOF MS for routine
identiﬁcation of bloodstream yeasts, especially Candida species.Materials and methodsYeast isolates and reference strains
C. albicans (ATCC-90028) and C. tropicalis (ATCC-6258) refer-
ence strains were used for the initial assessment of different
MALDI-TOF MS extraction protocols and as internal controls
for subsequent runs. Two sets of yeast isolates were used in this
study. A total of 354 strains (standardisation set) retrieved from
the National Culture Collection of Pathogenic Fungi (www.
nccpf.com), established at our department, were used for opti-
misation, standardisation and performance assessment of our
MALDI-TOF MS protocols. These strains were isolated from
intensive care unit–acquired candidemia patients admitted at 27
centres across India. Each strain was tested for purity, identiﬁed
by conventional biotyping [12] and conﬁrmed by sequencing of
the ITS2 and large subunit 28S ribosomal RNA gene’s D1/D2
regions [13]. A second set of 367 strains (validation set) isolated
from nosocomial candidemia patients admitted to our institution
from October 2013 to March 2014 were included to validate
our established MALDI-TOF MS protocols. These isolates were
directly subjected to MALDI-TOF MS analysis without prior
conﬁrmation by polymerase chain reaction (PCR) sequencing. In
all, a total of 723 Candida strains were used in this study.
Standardisation of sample extraction protocol
We initially evaluated three different MALDI-TOF MS sample
preparation protocols including the direct on-plate, on-plate
formic acid and off-plate extraction methods. For this stand-
ardisation we used the C. albicans (ATCC-90028) and C. tropi-
calis (ATCC-6258) reference strains. The strains were
subcultured on Sabouraud dextrose agar (SDA) at 37°C for 16
to 20 hours and fresh growth was used for further extraction.
The direct on-plate method was carried out as described by
the manufacturer. One to two isolated colonies of Candida
were spotted and air dried on a 96-target, polished steelClinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologyMALDI plate (Bruker Daltonik GmbH, Germany). The on-plate
formic acid extraction was carried out with some modiﬁcations
[11]. A loop-full of fresh Candida culture was emulsiﬁed in 1-mL
sterile double-distilled water (DDW) and vortexed in 1.5-mL
microcentrifuge tubes. The suspension was centrifuged at 13
000 rpm for 2 minutes, and the supernatant was discarded. This
was repeated twice. The pellet was re-suspended in 50 μL
sterile DDW. One microlitre of this suspension was spotted
and air dried in duplicate on the MALDI plate. The spots were
overlaid with 0.5 μL of 98% formic acid and again air dried. The
off-plate method also was carried out as previously described
[11]. A loop-full of fresh Candida culture was mixed in 300 μL
sterile DDW and brieﬂy vortexed; then 900 μL absolute
ethanol was mixed into this suspension and spun at 13 000 rpm
for 2 minutes. The supernatant was discarded, and the pellet
was air dried. It was resuspended in 50 μL of 70% formic acid
and 50 μL acetonitrile. The suspension was recentrifuged at 13
000 rpm for 2 minutes. One microlitre of suspension was
placed on the MALDI plate and air dried. Finally, for every
extraction method, 0.8 μL of matrix solution (100 μL of matrix
solution containing: 50 μL acetonitrile, 2.5 μL triﬂuoroacetic
acid, 1 mg α-cyano-4-hydroxycinnamic acid and 47.4 μL sterile
DDW) was added on each spot and allowed to air dry prior to
MALDI-TOF MS analysis.
Mass spectrum acquisition and analysis
All MALDI-TOF MS assays were carried out on a MALDI
Microﬂex LT mass spectrometer (Bruker Daltonik GmbH,
Bremen, Germany). Ionized spectra from each spot were ac-
quired in a linear positive mode at a laser frequency of 20 Hz
within a mass range from 2 to 20 kDa. Instrument calibration
was performed using the Bruker Bacterial Test Standard
Escherichia coli (#255343). MALDI BioTyper v1.1 was used for
automated smoothing, normalisation, baseline subtraction and
peak selection of different spectra. Signiﬁcant peaks were
selected to create sample proﬁles that were compared with the
MALDI BioTyper database using pattern-matching algorithms.
Results were expressed as log scores ranging from a value of
0 to 3. The manufacturer recommends 2 log score for species
identiﬁcation; 1.7 to 1.99 for genus identiﬁcation; and <1.7 as
unreliable. Any species misidentiﬁed or unavailable in the
manufacturer’s database was resolved by PCR sequencing [14].
Development of new mass spectrum proﬁles
Candida species unavailable in the MALDI Bio Typer database
were further analysed for constructing their mass spectrum
proﬁles. The new main spectrum projections (MSP) were
developed after identifying these strains by PCR sequencing. In
brief, the samples were extracted by on-plate formic acid
methods in triplicate. Eight technical replicates of theseand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 372–378
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Accordingly 24 spectra were acquired for every strain and
subjected to ﬂex analysis, smoothening and baseline subtrac-
tion. After analysis, the best 20 spectra were saved to the
MALDI Bio Typer database as the MSP of the new species.
Statistical analysis
Analysis and presentation of results were carried out as per the
Standards for Reporting of Diagnostic Accuracy guidelines. PCR
sequencing was used as the reference standard for all com-
parisons. Diagnostic test accuracy and reproducibility of
MALDI-TOF MS was assessed by computing species-speciﬁc
sensitivity, speciﬁcity, area under the curve and test efﬁciency
(kappa). To assess protocol performance, species-speciﬁc
receiver operating characteristics (ROC) cut-offs were
computed. Poststandardisation performance was assessed by
Student t test of species-speciﬁc MALDI-TOF log scores be-
tween standardisation and validation strains.ResultsAll three extraction methods correctly identiﬁed the C. albicans
(ATCC-90028) and C. tropicalis (ATCC-6258) reference strains.
However, statistical comparison of log scores revealed signiﬁcant
differences in direct on-plate extraction from the on-plate for-
mic acid extraction (C. albicans: 1.65 vs. 2.02, p 0.002; C. tropicalis:
1.55 vs. 2.16, p 0.003) and the off-plate extraction (C. albicans:
1.65 vs. 2.10, p 0.002; C. tropicalis: 1.55 vs. 2.07, p 0.002). There
were no signiﬁcant log score differences between the latter twoTABLE 1. Species-wise distribution of isolates across various MALD
Species Total number of isolates Missed by MALDI-TOF
C. tropicalis 165 1
C. parapsilosis 49 0
C. pelliculosa 23 0
C. krusei 21 0
C. glabrata 20 0
C. orthopsilosis 14 0
C. albicans 12 0
C. rugosa 11 2
C. auris 6 0
C. guilliermondii 6 0
Kodamaea ohmeri 5 0
Trichosporon asahii 5 0
C. catenulata 4 0
C. lipolytica 2 0
C. metapsilosis 2 0
C. nivariensis 2 0
C. viswanathii 2 0
C. intermedia 1 0
C. neoformans 1 0
C. pararugosa 1 0
C. utilis 1 0
Pichia jadinii 1 1
Total 354 04
MALDI-TOF, matrix-assisted laser desorption ionization time-of-ﬂight.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectmethods. Given its ease and efﬁciency, we adopted on-plate
formic acid extraction for the remaining study.
Standardisation of MALDI-TOF MS using the 354 strains
yielded a 98.9% concordance rate, with misidentiﬁcation of four
(1.1%) strains (Table 1, Fig. 1). We updated MALDI Bio Typer
database for missing species including C. auris, C. viswanathii and
Kodamaea ohmeri. MALDI-TOF correctly identiﬁed all of these
strains in the standardisation set using the new MSP proﬁles
incorporated into our instrument with log score >2 (Table 1).
Distribution of species-speciﬁc log scores (Table 1) showed
that the majority of strains (236 of 350; 67.5%) could be suc-
cessfully identiﬁed between scores of 1.70 and 1.99. The four
strains that were missed by MALDI-TOF included C. rugosa (2),
C. tropicalis (1) and Pichia jadinii (1).
In comparison to PCR sequencing, MALDI-TOF MS identi-
ﬁed yeasts with 100% accuracy with ROC cut off log score
>2.60 for C. auris, C. catenulate, C. glabrata, C. krusei, C. viswa-
nathii, K. ohmeri and Trichosporon asahii. Spectral cut-off
computed analysis showed 99.4% to 100% accuracy with
ROC cut-off log score of 1.70 for C. albicans, C. guilliermondii,
C. lipolytica, C. metapsilosis, C. nivariensis, C. orthopsilosis, C. par-
apsilosis, C. pelliculosa, C. rugosa and C. tropicalis (Table 2). The
overall predictive power, accuracy and efﬁciency of MALDI-
TOF MS were uniformly high and comparable to sequencing,
barring slight underperformance for C. tropicalis, C. rugosa and
C. parapsilosis.
MALDI-TOF analysis of the 367 validation set clinical isolates
successfully identiﬁed 359 (97.8%) isolates. A comparison of
species-speciﬁc log scores between the validation and stand-
ardisation sets showed no statistical difference, indicatingI Bruker scores for the standardisation set
Number of isolates with different Bruker score
<1.7 1.7–1.799 1.8–1.899 1.9–1.999 ‡2.0
0 40 30 56 38
0 7 6 19 17
0 6 6 6 5
0 0 2 4 15
0 2 0 3 15
0 7 4 2 1
0 2 3 4 3
0 5 2 2 0
0 0 0 0 6
0 3 1 2 0
0 0 0 0 5
0 1 0 1 3
0 0 2 0 2
0 0 2 0 0
0 1 1 0 0
0 2 0 0 0
0 0 0 0 2
0 0 0 0 1
0 1 0 0 0
0 0 0 1 0
0 0 0 0 1
0 0 0 0 0
0 77 59 100 114
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 372–378
FIG. 1. A doughnut chart depicting the species-speciﬁc distribution and performance of matrix-assisted laser desorption ionization time-of-ﬂight mass
spectrometry (inner ring) in comparison to polymerase chain reaction sequencing (outer ring) for the standardisation set of yeast strains. Numbers
indicate the number of strains identiﬁed by respective techniques.
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The MALDI-TOF MS assay accurately identiﬁed not only
common yeasts but also most of the uncommon ones, including
C. robusta, C. auris, C. utilis, C. lipolytica, C. kefyr, C. haemulonii,
C. fabianii, Magnusiomyces capitatus, Trichosporon asahii, Pseudo-
zyma aphidis, Rhodotorula mucilaginosa and K. ohmeri. The eightTABLE 2. Efﬁcacy of MALDI-TOF identiﬁcation in comparison to IT
Species
Number
of isolates
Correctly identiﬁed
n (%) Misidentiﬁed n (%)
C. tropicalis 165 164 (99.3%) 1 (0.6%)
C. parapsilosis 49 49 (100%) 0
C. pelliculosa 23 23 (100%) 0
C. krusei 21 21 (100%) 0
C. glabrata 20 20 (100%) 0
C. orthopsilosis 14 14 (100%) 0
C. albicans 12 12 (100%) 0
C. rugosa 11 9 (81.8%) 2 (18.2%)
C. guilliermondii 06 06 (100%) 0
C. auris 06 06 (100%) 0
Trichosporon asahii 05 05 (100%) 0
Kodamaea ohmeri 05 05 (100%) 0
C. catenulata 04 04 (100%) 0
C. lipolytica 02 02 (100%) 0
C. metapsilosis 02 02 (100%) 0
C. nivariensis 02 02 (100%) 0
C. viswanathii 02 02 (100%) 0
MALDI-TOF, matrix-assisted laser desorption ionization time-of-ﬂight; CI, conﬁdence interv
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyisolates that could not be reliably identiﬁed by MALDI-TOF MS
had log scores varying from 1.03 to 1.66. These isolates were
identiﬁed by sequencing ITS2 and D1/D2 region and included
four isolates of Wickerhamomyces anomalus, and two each of
Meyerozyma guilliermondii, and Cyberlindnera fabianii. None of
these species have their MSP in the Bruker BioTyper database.S2 and D1/D2 sequence identiﬁcation of select Candida species
Area under the
curve (95% CI)
Receiver-operator characteristic
cut-off log score Kappa (95% CI)
0.99 (0.98–1.00) 1.70 0.99 (0.98–1.00)
0.99 (0.98–0.99) >2.60 0.99 (0.97–1.00)
1.00 (0.99–100) 1.70 1.00 (1.00–1.00)
1.00 (0.99–1.00) >2.60 1.00 (1.00–1.00)
1.00 (0.99–1.00) >2.60 1.00 (1.00–1.00)
1.00 (0.99–1.00) 1.70 1.00 (1.00–1.00)
1.00 (0.99–1.00) 1.70 1.00 (1.00–1.00)
0.91 (0.87–0.94) 1.70 0.90 (0.76–1.00)
1.00 (0.99–1.00) 1.70 1.00 (1.00–1.00)
1.00 (0.99 -1.00) >2.60 1.00 (1.00–1.00)
1.00 (0.99–1.00) >2.60 1.00 (1.00–1.00)
1.00 (0.99–1.00) >2.60 1.00 (1.00–1.00)
1.00 (0.99–1.00) >2.60 1.00 (1.00–1.00)
1.00 (0.99–1.00) 1.70 1.00 (1.00–1.00)
1.00 (0.99–1.00) 1.70 1.00 (1.00–1.00)
1.00 (0.99–1.00) 1.70 1.00 (1.00–1.00)
1.00 (0.99–1.00) >2.60 1.00 (1.00–1.00)
al.
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 372–378
TABLE 3. Comparison of MALDI Bruker log scores for different species across the standardisation and validation sets
Species
Standardisation set Validation set
pNumber of isolates Mean log score ± SD (range) Number of isolates Mean log score ± SD (range)
C. tropicalis 165 1.90 ± 0.11 (1.70–2.32) 103 1.92 ± 0.13 (1.66–2.30) 0.34
C. parapsilosis 49 1.96 ± 0.11 (1.72–2.11) 24 1.95 ± 0.10 (1.75–2.12) 0.94
C. pelliculosa 23 1.89 ± 0.13 (1.70–2.20) 57 1.94 ± 0.13 (1.73–2.23) 0.16
C. krusei 21 2.09 ± 0.14 (1.88–2.32) 76 2.04 ± 0.15 (1.76–2.41) 0.16
C. glabrata 20 2.08 ± 0.15 (1.75–2.30) 20 2.06 ± 0.11 (1.84–2.21) 0.65
C. albicans 12 1.91 ± 0.10 (1.77–2.06) 39 1.87 ± 0.09 (1.71–2.12) 0.13
C. orthopsilosis 14 1.84 ± 0.12 (1.74–2.00) 6 1.81 ± 0.07 (1.73–1.91) 0.48
C. auris 6 2.44 ± 0.11 (2.30–2.55) 3 2.40 ± 0.19 (2.18–2.52) 0.73
C. guilliermondii 6 1.83 ± 0.08 (1.76–1.95) 11 1.84 ± 0.07 (1.75–1.97) 0.88
Kodamaea ohmeri 5 2.45 ± 0.09 (2.30–2.50) 3 2.37 ± 0.12 (2.30–2.50) 0.28
C. viswanathii 2 2.55 ± 0.07 (2.50–2.60) 6 2.44 ± 0.08 (2.30–2.50) 0.14
MALDI, matrix-assisted laser desorption ionization.
376 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIDiscussionMALDI-TOF MS is a robust tool for high-volume laboratory
services. MALDI-TOF MS can accurately identify fastidious
microorganisms in <3 hours, as compared to 2 to 7 days by
other conventional and molecular techniques. MALDI-TOF MS
is also being utilised for outbreak investigation [15,16]. Unlike
bacteria, few studies have evaluated the performance accuracy
of MALDI-TOF MS for high-throughput clinical identiﬁcation of
fungi. This has led to substantial variations in protocols for
sample preparation, MS analysis and development of MSP da-
tabases [15]. Most studies use empiric extraction methods.
Standardised protocols that can be universally applied to fungi
are needed for good reproducibility [17].
We evaluated different extraction protocols and found on-
plate formic acid extraction reliable and efﬁcient. Fungal cells
are larger and tougher than bacteria, needing stronger reagents
for MALDI-TOF MS ionization [15]. The off-plate method
achieves this effectively, but the extra steps render it costlier
and time consuming. The direct on-plate method, on the other
hand, is faster and consumes fewer resources, but inadequate
fungal proteins extraction yields lower log scores. The on-plate
formic acid extraction achieves a good balance between these
two techniques. Whereas acetonitrile enhances protein solu-
bility, 98% formic acid hastens extraction (3 to 5 minutes) and
improves log scores, as seen in our study. Similar efﬁcacy of this
method has been noted in bacterial studies [18,19]. We found
SDA an acceptable medium for MALDI-TOF MS. Thorough
washing of cells prevented interference from culture medium
proteins, yielding reproducible spectral scores.
Our study has several strengths, which set a precedent for
MALDI-TOF MS identiﬁcation of clinical yeasts. Most studies
examine only reference strains without validating their protocol
on blind clinical strains. We demonstrate that validation veriﬁes
standardisation and helps identify and develop MSPs missing inClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe MALDI Bio Typer database. Further, we have compared
manufacturer’s log scores against statistically generated ROC
cut-offs. This clearly depicts how the identiﬁcation efﬁciency of
our assay is varying with respect to log scores, and which
species need greater representation in the MSP database to
further enhance performance.
Our assay missed 4 of 354 strains from the standardisation
set, which included two strains of C. rugosa, one C. tropicalis and
one Pichia jadinii. Pichia jadinii is poorly represented in the
Bruker database, as true for other uncommon yeasts [20]. The
misidentiﬁcation of C. rugosa and C. tropicalis indicate subtle but
signiﬁcant variations in our regional strains, which are probably
underrepresented in the Bruker database. Poor identiﬁcation
and log scores can have several causes. We maintained rigorous
quality control to circumvent causes such as strain impurity,
older (>48 hours) yeast colonies, culture condition differences,
inefﬁcient protein extraction and contamination by culture
medium proteins [21]. Aside from technical factors, qualitative
and quantitative variations in intraspecies protein expression
and underrepresentation of such strain variations in MALDI Bio
Typer database are signiﬁcant causes of such misidentiﬁcations/
nonidentiﬁcations. Such variations have been reported earlier
from different regions [21]. Further, our assay failed to identify
8 of 367 isolates from the validation set. These comprised
Cyberlindnera fabianii, Meyerozyma guilliermondii and Wick-
erhamomyces anomalus, none of which are present in the Bruker
database.
Although the manufacturer recommends a log score 2.0
for species identiﬁcation, ROC analysis of our data revealed
that a log score cut-off 1.7 can unambiguously identify a
majority of the species. However a few species, including
C. auris, C. catenulate, C. glabrata, C. krusei, C. viswanathii, Koda-
maea ohmeri and Trichosporon asahii, showed higher log score
cut-offs (2.60). This difference indicates that these species do
not have sufﬁcient entries in the Bruker database to capture all
variations among our isolates. MSP for C. auris, C. visvanathii andious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 372–378
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were constructed in this study. Furthermore, log score cut-offs
for new species tend to be higher if a small number of isolates
(two each in our case) are used to create the MSP. In addition,
because all of these strains were from a single centre, the
spectral variation expected is minimal and this may have
contributed to the high score. These ﬁndings highlight two is-
sues. First, although the manufacturer recommends a stringent
score of 2.0 for reliable species identiﬁcation, this does not
invalidate correct identiﬁcation at scores <2.0. Previous studies
have shown that supplementing the Bruker database with in-
house spectra enhances the speciﬁcity of identiﬁcation even
at lower log scores [20,22]. Increasing species-speciﬁc entries
better captures proteomic variations and helps the pattern-
matching algorithm to learn and become more proﬁcient
[23]. Secondly, regular, systematic expansion and calibration of
the MALDI-TOF database with carefully identiﬁed strains of
different species is important. This enhances the spectral proﬁle
of underrepresented species, adds completely missing uncom-
mon species, accounts for geographical genotypic and pheno-
typic variations, captures emerging species and monitors time
trends within species [15,24,25]. Such supplementary libraries
can either be queried separately or merged with existing li-
braries [20].
Despite its several advantages, MALDI-TOF MS requires
substantial initial set-up cost, needs molecular diagnostics for
identifying missing species and is yet to develop a global data-
base of all common and uncommon pathogens [20]. Our study
also was limited by the low number of strains for uncommon
yeasts. These species are being regularly monitored, and as
their numbers grow their MSP proﬁles will be upgraded for
better MALDI-TOF MS performance.
In conclusion, our study demonstrates the utility of MALDI-
TOF MS for rapid and accurate identiﬁcation of bloodstream
yeasts. Proper standardisation, validation and statistical inter-
pretation of MALDI-TOF MS results are essential for identifying
assay deﬁciencies and enhancing performance. MALDI-TOF MS
promises to be a useful tool for routine patient care, rapid
diagnostics and outbreak investigation.Transparency declarationThe authors declare that they have no conﬂicts of interest.References[1] Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of
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